iiinova — where your digital self keeps evolving

Reposted by Elias Sotirchos

NEJM.org @nejm.org · 01/07/2026

Among patients with newly diagnosed relapsing multiple sclerosis, rituximab was noninferior to ocrelizumab in preventing new or enlarging lesions on MRI. The risk of serious adverse events was similar in the two groups. Full phase 3 OVERLORD-MS trial results: nej.md/3QJuaep

A graph from an Original Article published in the New England Journal of Medicine article titled "Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis." The figure shows graphs of the primary end point. Panel A indicates no new or enlarging lesions on T2-weighted MRI, while Panel B shows a noninferiority test. The trial name, OVERLORD-MS, is in parentheses after the title.

083

Reposted by Elias Sotirchos

Jenna Norton @jenna-m-norton.bsky.social · 30/04/2026

Sharing this screen grab from a friend at NIH (with permission). This is a checklist program officers have to complete before a grant can be awarded. The first question: "Is this grant All Clean/Clear in the NIH Text analysis Tool?" 🧵1/3

Screen grab of an NIH grants checklist showing the first question is: "1. Is this grant All Clean/Clear in the NIH Text analysis Tool?"

15446292

Reposted by Elias Sotirchos

Don Moynihan @donmoyn.bsky.social · 24/01/2026

Media: do not lead with the false government framing of what happened

8354431014

Reposted by Elias Sotirchos

Dimitri Drekonja, MD, MS @dimitridrekonja.bsky.social · 24/01/2026

Alex from our time working together, while he was in nursing school. Later, he moved to ICU, working as a nurse to support critically ill Veterans. He had such a great attitude. We’d chat between patients about trying to get in a mountain bike ride together. Will never happen now

Alex Pretti from his early days working at the VA

626234997711

Reposted by Elias Sotirchos

brandon-beaber.bsky.social @brandon-beaber.bsky.social · 06/01/2026

The FDA explains its rejection of the multiple sclerosis drug tolebrutinib in a Complete Response Letter (CRL). "A favorable benefit-risk profile could not be established for any patient subpopulation" download.open.fda.gov/crl/CRL_NDA2...

download.open.fda.gov

155

Reposted by Elias Sotirchos

The Sumaira Foundation (TSF) @thesumairafdn.bsky.social · 15/04/2025

#ICYMI We were joined by Dr. Elias Sotirchos to discuss vaccines in the setting of immunocompromised patients. www.youtube.com/watch?v=7VCE... This program was made possible with support from Alexion Pharmaceuticals

youtube.com

Immunizations for the Immunocompromised

YouTube video by The Sumaira Foundation

043

Reposted by Elias Sotirchos

LPJ Lab - Neuroimmunometabolism @lpjlab.org · 10/03/2025

#URGENT: #MultipleSclerosis research funding at risk: contact Congress today! The Continuing Resolution to fund the government cuts funding by 57% The #MS Society has an action alert urging Members of Congress to oppose these cuts here nmss.quorum.us/campaign/113... Please take action and #share!

nmss.quorum.us

URGENT: MS Research Funding at Risk – Contact Congress Today

ACTION NEEDED TODAY

0106

Reposted by Elias Sotirchos

Joe Sabatino @jsabatino37.bsky.social · 13/02/2025

Pleased to write this editorial with Larry Steinman about a potential novel antibody in MS www.neurology.org/doi/10.1212/... Original manuscript here: www.neurology.org/doi/10.1212/...

neurology.org

Neurology® Journals

1113

Reposted by Elias Sotirchos

More Perfect Union @moreperfectunion.bsky.social · 12/12/2024

A bill to break up UnitedHealth, CVS, Cigna and more has been introduced by a bipartisan group of U.S. senators and representatives. The legislation would force insurers to sell their pharmacy businesses. It aims to combat PBMs, pharma middlemen who drive up costs.

16069711556

Elias Sotirchos @esotirchos.bsky.social · 04/12/2024

jnnp.bmj.com/content/earl... This is an interesting study. Need to be careful though with potentially overinterpreting this and other retrospective observational studies purported to prove the effectiveness of early PLEX. My detailed rapid response to this article here: jnnp.bmj.com/content/earl...

jnnp.bmj.com

Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks

Background Incomplete attack remission is the main cause of disability in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Apheresis therapies such as plasma exchange and immun...

162

Reposted by Elias Sotirchos

Stacey L. Clardy @staceylclardy.bsky.social · 20/11/2024

Time to strike the label “Lupus Myelitis” … Forever ✅ What say you, #MedSky #RheumSky #NeuroSky? 🧠🎙️ Neurology Podcast: Dr. @esotirchos.bsky.social discusses the underlying etiologies of myelitis in patients with rheumatologic disease. Listen now: bit.ly/48VRPwC

bit.ly

Myelitis Associated With Rheumatologic Disease

Dr. Stacey Clardy talks with Dr. Elias Sotirchos about the underlying etiologies of myelitis in patients with rheumatologic disease. Read the related article in . Disclosures can be found at Neurology...

0164